Bruker Corporation $BRKR Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its holdings in Bruker Corporation (NASDAQ:BRKR) by 0.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,404,261 shares of the medical research company’s stock after selling 27,612 shares during the quarter. Vanguard Group Inc. owned about 6.86% of Bruker worth $338,034,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Orbis Allan Gray Ltd acquired a new position in Bruker in the 2nd quarter valued at about $192,735,000. AQR Capital Management LLC raised its position in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the period. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Bruker in the 2nd quarter valued at $62,032,000. Norges Bank purchased a new position in shares of Bruker during the 2nd quarter worth $44,459,000. Finally, Vaughan Nelson Investment Management L.P. increased its position in shares of Bruker by 61.6% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after purchasing an additional 796,510 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Stock Down 2.2%

Shares of NASDAQ:BRKR opened at $40.11 on Friday. The firm has a 50 day simple moving average of $45.64 and a 200-day simple moving average of $40.79. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $56.22. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $6.09 billion, a PE ratio of -267.40, a P/E/G ratio of 2.45 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The company had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. Bruker’s revenue was down .2% on a year-over-year basis. During the same period last year, the firm earned $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s payout ratio is currently -133.33%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BRKR. Citigroup lowered their target price on Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a report on Friday, February 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th. Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a research note on Wednesday, December 10th. Jefferies Financial Group set a $50.00 price objective on Bruker in a research note on Thursday, February 12th. Finally, Rothschild & Co Redburn set a $60.00 target price on Bruker in a research note on Thursday, November 20th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Bruker presently has a consensus rating of “Hold” and an average price target of $50.38.

Insider Activity

In related news, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $7,064,365. This represents a 5.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 27.30% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.